文献速递胸部肿瘤

BRAF G469V突变驱动肺癌对EGFR酪氨酸激酶抑制剂敏感

Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors.
PubMed 文献 · J Thorac Oncol · 2021-10-12

本研究通过患者来源异种移植模型和细胞系发现,携带BRAF G469V突变的肺腺癌细胞对多种EGFR酪氨酸激酶抑制剂敏感,该突变是致癌驱动因素,且EGFR TKIs可直接靶向抑制BRAF G469V。结论提示临床已批准的EGFR TKIs可重新用于治疗携带BRAF G469V突变的非小细胞肺癌患者。

要点

  • BRAF G469V是肺腺癌的致癌驱动突变。
  • 携带BRAF G469V的模型对EGFR TKIs敏感。
  • EGFR TKIs可直接抑制BRAF G469V激酶活性。

核心结论

  • 临床已批准的EGFR酪氨酸激酶抑制剂可重新用于治疗携带BRAF G469V突变的非小细胞肺癌患者。

研究设计与样本

  • 研究使用一例肺腺癌患者来源异种移植模型PHLC12(EGFR野生型且非扩增)及其衍生细胞系X12CL,评估EGFR TKIs的敏感性。
  • 通过小干扰RNA敲低、激酶实验、结构建模、分子动力学模拟和结合实验探究BRAF G469V作为驱动基因及EGFR TKIs的直接靶向机制。

主要发现

  • PHLC12和X12CL对多种EGFR TKIs敏感。
  • BRAF G469V是该模型中唯一已知的致癌突变,敲低BRAF而非EGFR可杀死X12CL细胞。
  • 从X12CL分离的BRAF蛋白激酶活性可被吉非替尼和奥希替尼抑制。
  • 在非EGFR表达的NR6细胞中表达BRAF G469V可促进低血清条件下的生长,且对EGFR TKIs敏感。
  • 结构建模、分子动力学模拟和体外结合实验支持BRAF G469V是TKIs的直接靶点。

临床怎么用

  • 对于携带BRAF G469V突变的非小细胞肺癌患者,可考虑使用已批准的EGFR酪氨酸激酶抑制剂进行治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Mutations in BRAF occur in 2% to 4% of patients with lung adenocarcinoma. Combination dabrafenib and trametinib, or single-agent vemurafenib is approved only for patients with cancers driven by the V600E BRAF mutation. Targeted therapy is not currently available for patients harboring non-V600 BRAF mutations. METHODS: A lung adenocarcinoma patient-derived xenograft model (PHLC12) with wild-type and nonamplified EGFR was tested for response to EGFR tyrosine kinase inhibitors (TKIs). A cell line derived from this model (X12CL) was also used to evaluate drug sensitivity and to identify potential drivers by small interfering RNA knockdown. Kinase assays were used to test direct targeting of the candidate driver by the EGFR TKIs. Structural modeling including, molecular dynamics simulations, and binding assays were conducted to explore the mechanism of off-target inhibition by EGFR TKIs on the model 12 driver. RESULTS: Both patient-derived xenograft PHLC12 and the X12CL cell line were sensitive to multiple EGFR TKIs. The BRAFG469V mutation was found to be the only known oncogenic mutation in this model. Small interfering RNA knockdown of BRAF, but not the EGFR, killed X12CL, confirming BRAFG469V as the oncogenic driver. Kinase activity of the BRAF protein isolated from X12CL was inhibited by treatment with the EGFR TKIs gefitinib and osimertinib, and expression of BRAFG469V in non-EGFR-expressing NR6 cells promoted growth in low serum condition, which was also sensitive to EGFR TKIs. Structural modeling, molecular dynamic simulations, and in vitro binding assays support BRAFG469V being a direct target of the TKIs. CONCLUSIONS: Clinically approved EGFR TKIs can be repurposed to treat patients with non-small cell lung cancer harboring the BRAFG469V mutation.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Huo KG, Notsuda H, Fang Z, et al. Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors. J Thorac Oncol. 2021. PMID: 34648945. doi:10.1016/j.jtho.2021.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。